Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; 29 of the 41 sources its claims cite were checked for support.

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.

Open access

Abstract

Outcomes are poor in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens were randomized 2:1 to idecabtagene vicleucel (ide-cel) or standard regimens (SRs). An interim analysis (IA) demonstrated significantly longer median progression-free survival (PFS; primary end point; 13.3 vs 4.4 months; P < .0001) and higher overall response rate (ORR) with ide-cel vs SRs. At final PFS analysis (median follow-up, 30.9 months), ide-cel further improved median PFS vs SRs (13.8 vs 4.4 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.38-0.63). PFS benefit with ide-cel vs SRs was observed regardless of number of prior lines of therapy, with greatest benefit after 2 prior lines (16.2 vs 4.8 months, respectively). ORR benefit was maintained with ide-cel vs SRs (71% vs 42%; complete response, 44% vs 5%). Patient-centric design allowed crossover from SRs (56%) to ide-cel upon progressive disease, confounding overall survival (OS) interpretation. At IA of OS, median was 41.4 (95% CI, 30.9 to not reached [NR]) vs 37.9 (95% CI, 23.4 to NR) months with ide-cel and SRs, respectively (HR, 1.01; 95% CI, 0.73-1.40); median OS in both arms was longer than historical data (9-22 months). Two prespecified analyses adjusting for crossover showed OS favoring ide-cel. This trial highlighted the importance of individualized bridging therapy to ensure adequate disease control during ide-cel manufacturing. Ide-cel improved patient-reported outcomes vs SRs. No new safety signals were reported. These results demonstrate the continued favorable benefit-risk profile of ide-cel in early-line and TCE R/RMM. This trial was registered at www.ClinicalTrials.gov as #NCT03651128.

Overview

CoChat Summary

## TL;DR

In the preplanned final KarMMa-3 analysis with 30.9 months median follow-up, ide-cel continued to outperform standard regimens in triple-class-exposed relapsed/refractory multiple myeloma, with median PFS 13.8 vs 4.4 months and ORR 71% vs 42%. Overall survival was confounded by crossover, but crossover-adjusted analyses showed a trend favoring ide-cel, and safety remained consistent with prior reports.

## Key findings

  • Median PFS was 13.8 months with ide-cel vs 4.4 months with standard regimens (HR 0.49; 95% CI, 0.38-0.63) at 30.9 months median follow-up.
  • PFS benefit was seen across prior lines of therapy, with median PFS of 16.2 vs 4.8 months after 2 prior lines, 13.6 vs 3.4 months after 3 prior lines, and 11.2 vs 4.8 months after 4 prior lines.
  • ORR was 71% with ide-cel vs 42% with standard regimens; CR rate was 44% vs 5%, and MRD-negative CR rate in evaluable patients was 35% vs 2%.
  • Median OS was 41.4 months with ide-cel vs 37.9 months with standard regimens (HR 1.01; 95% CI, 0.73-1.40), but crossover-adjusted sensitivity analyses favored ide-cel (HR 0.72 and 0.87 in two prespecified models; post hoc IPCW HR 0.74).

## Methods

  • KarMMa-3 was an international, randomized, open-label phase 3 trial in patients aged ≥18 years who had received 2 to 4 prior antimyeloma therapies including daratumumab, an immunomodulatory agent, and a proteasome inhibitor, with progressive disease within 60 days of last prior therapy.
  • 386 patients were randomized 2:1 to ide-cel (n=254) or one of 5 investigator-selected standard regimens (n=132); after protocol amendment, crossover from standard regimens to ide-cel was allowed upon IRC-confirmed progression.
  • Primary analysis was PFS by blinded independent review committee in the ITT population; secondary analyses included ORR, OS, MRD-negative CR, PFS2, HRQOL, and safety, with time-to-event outcomes analyzed by Kaplan-Meier and Cox models and OS sensitivity analyses adjusting for crossover.

## Limitations

  • The paper states that the crossover design confounded OS interpretation.
  • The text also notes that some bridging therapy may have insufficiently controlled disease before ide-cel infusion, contributing to early deaths; this is an evidence-based concern evident from the trial conduct and early-death pattern.
  • No additional limitations are stated in the paper beyond prior reported KarMMa-3 limitations and crossover-related OS confounding.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1182/blood.2024024582

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 CONSORT diagram. In the SRs arm, 1 of 5 SRs was chosen before randomization for each patient by the investigator. The safety population included all the patients in the ITT (randomized) population who underwent leukapheresis or received bridging therapy, lymphodepleting chemotherapy, or ide-cel (ide-cel arm) or who received any dose of daratumumab, pomalidomide, lenalidomide, bortezomib, ixazomib, car fi lzomib, elotuzumab, or dexamethasone (SRs arm). The treated population included all patients who received the treatment to which they were randomly assigned. Of 254 patients in the ide-cel arm in the ITT population, 249 underwent leukapheresis (safety population), 212 received bridging therapy, 227 received lymphocyte-depleting chemotherapy, and 225 received a single infusion of ide-cel. Five patients in the SRs arm had con fi rmed PD before treatment crossover to ide-cel was permitted after protocol amendment 2; instead, they received other subsequent antimyeloma therapies. DPd, daratumumab, pomalidomide, and dexamethasone; DVd, daratumumab, bortezomib, and dexamethasone; EPd, elotuzumab, pomalidomide, and dexamethasone; IRd, ixazomib, lenalidomide, and dexamethasone; Kd, car fi lzomib and dexamethasone.
Figure 1 CONSORT diagram. In the SRs arm, 1 of 5 SRs was chosen before randomization for each patient by the investigator. The safety population included all the patients in the ITT (randomized) population who underwent leukapheresis or received bridging therapy, lymphodepleting chemotherapy, or ide-cel (ide-cel arm) or who received any dose of daratumumab, pomalidomide, lenalidomide, bortezomib, ixazomib, car fi lzomib, elotuzumab, or dexamethasone (SRs arm). The treated population included all patients who received the treatment to which they were randomly assigned. Of 254 patients in the ide-cel arm in the ITT population, 249 underwent leukapheresis (safety population), 212 received bridging therapy, 227 received lymphocyte-depleting chemotherapy, and 225 received a single infusion of ide-cel. Five patients in the SRs arm had con fi rmed PD before treatment crossover to ide-cel was permitted after protocol amendment 2; instead, they received other subsequent antimyeloma therapies. DPd, daratumumab, pomalidomide, and dexamethasone; DVd, daratumumab, bortezomib, and dexamethasone; EPd, elotuzumab, pomalidomide, and dexamethasone; IRd, ixazomib, lenalidomide, and dexamethasone; Kd, car fi lzomib and dexamethasone.From the PDF
Figure 2 Kaplan-Meier curves showing progression-free survival in the intent-to-treat population and by number of prior lines of therapy. PFS overall (A; primary end point; ITT population) and by number of prior LoT (B; prespeci fi ed subgroup analysis, per protocol; ITT population). PFS was analyzed in the ITT population of all randomized patients in both arms and included early PFS events occurring between randomization and ide-cel infusion. PFS based on IMWG criteria per IRC. *Based on KM approach. † Strati fi ed HR based on univariate Cox proportional hazard model. CI is 2-sided. IMWG, International Myeloma Working Group; SE, standard error.
Figure 2 Kaplan-Meier curves showing progression-free survival in the intent-to-treat population and by number of prior lines of therapy. PFS overall (A; primary end point; ITT population) and by number of prior LoT (B; prespeci fi ed subgroup analysis, per protocol; ITT population). PFS was analyzed in the ITT population of all randomized patients in both arms and included early PFS events occurring between randomization and ide-cel infusion. PFS based on IMWG criteria per IRC. *Based on KM approach. † Strati fi ed HR based on univariate Cox proportional hazard model. CI is 2-sided. IMWG, International Myeloma Working Group; SE, standard error.From the PDF
Figure 3 Kaplan-Meier curves showing overall survival in the intent-to-treat population and adjusting for crossover. OS (ITT population; A) and OS sensitivity analysis adjusted for crossover* (B). *Two-stage Weibull model without recensoring (prespeci fi ed analysis). † Based on KM approach. ‡ Strati fi ed HR is based on the univariate Cox proportional hazards model. CI is 2-sided and calculated by bootstrap method.
Figure 3 Kaplan-Meier curves showing overall survival in the intent-to-treat population and adjusting for crossover. OS (ITT population; A) and OS sensitivity analysis adjusted for crossover* (B). *Two-stage Weibull model without recensoring (prespeci fi ed analysis). † Based on KM approach. ‡ Strati fi ed HR is based on the univariate Cox proportional hazards model. CI is 2-sided and calculated by bootstrap method.From the PDF
Figure 4 Kaplan-Meier curve showing postprogression survival in patients in the standard regimens arms who did or did not crossover to ide-cel. Postprogression survival in patients in the SRs arm who crossed over* vs did not crossover to ide-cel. *Based on KM methods. Patients who underwent leukapheresis with or without ide-cel infusion. Postprogression survival was de fi ned as time from PD (IRC adjudicated) to death due to any cause.
Figure 4 Kaplan-Meier curve showing postprogression survival in patients in the standard regimens arms who did or did not crossover to ide-cel. Postprogression survival in patients in the SRs arm who crossed over* vs did not crossover to ide-cel. *Based on KM methods. Patients who underwent leukapheresis with or without ide-cel infusion. Postprogression survival was de fi ned as time from PD (IRC adjudicated) to death due to any cause.From the PDF

Verification

Claims the paper makes

16 Valid · 0 Not valid · 2 Not checked · 62 Own results and interpretations

36 more claims · 2 with their cited sources checked

Create a free account to see all 80 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 35
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 29 references

Research works printed but not linked: 2

  1. 2010, Common Terminology Criteria for Adverse Events (CTCAE) v4. 03
  2. 2018, Question and Answer on Adjustment for Cross-Over in Estimating Effects in Oncology Trials

Cited by

See all 79

Metadata

Authors
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S., Abrahamsen, I. W., Baz, R., Broijl, A., Chen, C., Jagannath, S., Raje, N., Scheid, C., Delforge, M., Benjamin, R., Pabst, T., Iida, S., Berdeja, J., Giralt, S., Truppel-Hartmann, A., Chen, Y., Zhong, X., Wu, F., Piasecki, J., Eliason, L., Dhanda, D., Felten, J., Caia, A., Cook, M., Popa McKiver, M., & Rodríguez-Otero, P.
Affiliations
  • Mayo Clinic in Florida (US)
  • Université Paris Cité (FR)
  • The University of Texas MD Anderson Cancer Center (US)
  • 4Department of Medical and Surgical Sciences, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
  • Emory University (US)
  • Université de Lille (FR)
  • University of Wisconsin–Madison (US)
  • University of Alabama at Birmingham (US)
  • Washington University in St. Louis (US)
  • University of Calgary (CA)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Northside Hospital (US)
  • Oslo University Hospital (NO)
  • Moffitt Cancer Center (US)
  • Erasmus MC Cancer Institute (NL)
  • Princess Margaret Cancer Centre (CA)
  • Tisch Cancer Institute (US)
  • Massachusetts General Hospital (US)
  • University of Cologne (DE)
  • Universitair Ziekenhuis Leuven (BE)
  • King's College Hospital (GB)
  • University Hospital of Bern (CH)
  • Nagoya City University (JP)
  • Sarah Cannon (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • 262seventy bio, Cambridge, MA
  • Bristol-Myers Squibb (United States) (US)
  • Bristol-Myers Squibb (Switzerland) (CH)
  • 27Bristol Myers Squibb, Princeton, NJ
  • 29Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain
Corresponding author
Ailawadhi, Sikander
Venue
Blood
Published
2024-12-05
Volume
144
Issue
23
Pages
2389-2401
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4401942365
Cited by
79
References
29
Citations by year
2026: 40 · 2025: 34 · 2024: 5
FWCI
24.40
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Gilead Sciences
  • American Society of Clinical Oncology
  • Celgene
  • National Cancer Research Institute
  • Regeneron Pharmaceuticals
  • BeiGene
  • Chugai Pharmaceutical
  • Pharmacyclics
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Keywords
idecabtagene vicleucel, relapsed/refractory multiple myeloma, CAR T-cell therapy, progression-free survival, overall survival, crossover, patient-reported outcomes, prior lines of therapy, complete response, safety signals, benefit-risk profile, CAR T cell manufacturing
MeSH terms
Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Immunotherapy, Adoptive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. https://app.cochat.ai/papers/10.1182/blood.2024024582
The paper
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S., Abrahamsen, I. W., Baz, R., Broijl, A., Chen, C., Jagannath, S., Raje, N., Scheid, C., . . . Rodríguez-Otero, P. (2024). Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. https://doi.org/10.1182/blood.2024024582

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.